Meridian Bioscience Inc (VIVO): Catherine Sazdanoff , director of Meridian Bioscience Inc purchased 7,700 shares on Apr 29, 2016. The Insider buying transaction was reported by the company on May 2, 2016 to the Securities and Exchange Commission. The shares were purchased at $19.20 per share for a total value of $147,843.84 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 10, 2015, Vecheslav A Elagin (EVP, Research & Development) sold 7,500 shares at $19.75 per share price.On Dec 2, 2015, Richard Eberly (EVP,Pres Meridian Life Science) sold 4,934 shares at $19.61 per share price.Also, On Nov 24, 2015, John Mcilwraith (director) purchased 1,000 shares at $20.19 per share price.On Mar 3, 2015, Marviette D. Johnson (VP, Human Resources) sold 1,917 shares at $19.91 per share price.
Meridian Bioscience: On Wednesday, Apr 27, 2016 heightened volatility was witnessed in Meridian Bioscience which led to swings in the share price. The shares opened for trading at $20.6 and hit $20.74 on the upside , eventually ending the session at $20.69, with a gain of 0.68% or 0.14 points. The heightened volatility saw the trading volume jump to 1,84,978 shares. The 52-week high of the share price is $21.4 and the company has a market cap of $870 M . The 52-week low of the share price is at $16.6.
Company has been under the radar of several Street Analysts.Meridian Bioscience is Reiterated by Canaccord Genuity to Hold and the brokerage firm has raised the Price Target to $ 19 from a previous price target of $18 .The Rating was issued on Mar 28, 2016.
Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.